MICaB Graduate Program
Main navigation |
Walter C. Low, Ph.D.
Department of Neurosurgery
Michigan, 1979, Ph.D.
612-626-9200 - office
Brain and tumor immunology and development of cancer vaccines
My laboratory is focused on the study of brain tumors. Primary tumors
that originate in the brain represent some of the most malignant types
of cancers. Patients diagnosed with grade IV glioblastoma multiforme have
a mean survival time of 11 months after diagnosis. Our studies of brain
tumors have emphasized the development of immunotherapeutic approaches
for the treatment of these tumors. Cancer vaccines consisting of cytokines
and tumor antigens are used to stimulate cells of the immune system to
recognize and destroy tumors within the brain.
Selected Recent Publications:
- Jean, WC, SR Spellman,
MA Wallenfriedman, WA Hall, and WC Low, Interleukin-12 based immunotherapy
against rat 9L glioma. Neurosurgery
42: 850-856, 1998.
- Wallenfriedman, MA, JA
Conrad, L DelaBarre, PC Graupman, G Lee, M Garwood, DS Gregerson, WC
Jean, WA Hall, and WC Low, Effects of continuous localized infusion
of granulocyte/macrophage colony stimulating factor (GM-CSF) and inoculations
of irradiated glioma cells on tumor regression, Journal
of Neurosurgery 90:1064-1071, 1999.
- Ni, H.T., S.R. Spellman, W.C. Jean, W.A. Hall, and W.C. Low, Immunization
with dendritic cells pulsed with tumor extract increases survival of
mice bearing intracranial gliomas, Journal
of Neuro-Oncology, 51:1-9 (2001).
- Wu AH and WC Low, Molecular cloning of the rat IL-13 alpha 2 receptor cDNA and its expression in rat tissues, Journal of Neuro-Oncology 59:99-105 (2002). Abstract
- Wu AH and WC Low, Molecular cloning and Identification of the human interleukin 13 alpha 2 receptor (IL-13Ra2) promoter, Neuro-Oncology 5:179-187 (2003). Abstract
- Jean, WC, SR Spellman, MA Wallenfriedman, WA Hall, and WC Low, Effects of combined granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2, and interleukin-12 based immunotherapy against intracranial glioma in the rat, Journal of Neuro-Oncology 66:39-49 (2004). Abstract
- Wu AH, WA Hall, and WC Low, Identification of HLA a*0201 glioblastoma multiforme cell lines for immunotherapy by PCR-SSP and DNA sequencing, Journal of Neuro-Oncology 66:1-8 (2004). Abstract
- Wu AH, J Xiao, L. Anker, WA Hall, DS Gregerson, WK Cavenee, W Chen, and WC Low, Identification of EGFRvIII-derived epitopes restricted by HLA A0201 for dendritic cell based immunotherapy of gliomas, Journal of Neuro-Oncology (e-pub ahead of print, Sept. 2, 2005). Abstract
- Ohlfest JR, Demorest ZL, Motooka Y, Vengco I, Oh S, Chen E, Scappaticci FA, Saplis RJ, Ekker SC, Low WC, Freese AB, and Largaespada DA. Combinatorial antiangiogenic gene therapy by nonviral gene transfer using the Sleeping Beauty transposon causes tumor regression and improves survival in mice bearing intracranial human glioblastoma. Molecular Therapy (e-pub ahead of print, Sept. 5, 2005). Abstract
Last updated: October 3, 2005